WO2022270987A1 - Aurka 선택적 분해 유도 화합물 - Google Patents
Aurka 선택적 분해 유도 화합물 Download PDFInfo
- Publication number
- WO2022270987A1 WO2022270987A1 PCT/KR2022/009074 KR2022009074W WO2022270987A1 WO 2022270987 A1 WO2022270987 A1 WO 2022270987A1 KR 2022009074 W KR2022009074 W KR 2022009074W WO 2022270987 A1 WO2022270987 A1 WO 2022270987A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- mmol
- cancer
- synthesis
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 270
- 230000008684 selective degradation Effects 0.000 title claims abstract description 12
- 230000001939 inductive effect Effects 0.000 title description 15
- 101150095401 AURKA gene Proteins 0.000 title 1
- 101100111052 Xenopus laevis aurka-a gene Proteins 0.000 title 1
- 101100111053 Xenopus laevis aurka-b gene Proteins 0.000 title 1
- 102000004000 Aurora Kinase A Human genes 0.000 claims abstract description 69
- 108090000461 Aurora Kinase A Proteins 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 51
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims abstract description 16
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 3
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000023514 Barrett esophagus Diseases 0.000 claims description 2
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 206010006220 Breast cyst Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims description 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 206010025280 Lymphocytosis Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 201000003149 breast fibroadenoma Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002575 ocular melanoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000003708 skin melanoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 206010048832 Colon adenoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 208000014081 polyp of colon Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 15
- 239000000126 substance Substances 0.000 abstract description 7
- 230000001588 bifunctional effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 240
- 230000015572 biosynthetic process Effects 0.000 description 237
- 238000003786 synthesis reaction Methods 0.000 description 233
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 224
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 180
- 239000000203 mixture Substances 0.000 description 171
- 238000006243 chemical reaction Methods 0.000 description 170
- 239000000243 solution Substances 0.000 description 167
- 230000002829 reductive effect Effects 0.000 description 161
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 144
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 133
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 131
- 235000019439 ethyl acetate Nutrition 0.000 description 120
- 239000007787 solid Substances 0.000 description 114
- 239000011734 sodium Substances 0.000 description 102
- 239000012074 organic phase Substances 0.000 description 101
- -1 aromatics Substances 0.000 description 91
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 89
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 83
- 239000011541 reaction mixture Substances 0.000 description 75
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 74
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 72
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 60
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 53
- 239000012267 brine Substances 0.000 description 52
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 45
- 239000007858 starting material Substances 0.000 description 44
- 238000002474 experimental method Methods 0.000 description 42
- 230000008569 process Effects 0.000 description 40
- 239000012071 phase Substances 0.000 description 39
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 39
- 238000002953 preparative HPLC Methods 0.000 description 38
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 37
- 239000003208 petroleum Substances 0.000 description 37
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 35
- 238000005160 1H NMR spectroscopy Methods 0.000 description 35
- JLHUENQHQNAMIR-CERRFVOPSA-N tert-butyl N-[2-[2-[2-[[(2S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]amino]-2-oxoethoxy]ethoxy]ethyl]carbamate Chemical compound CC([C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)NCC1=CC=C(C=2SC=NC=2C)C=C1)O)NC(=O)COCCOCCNC(=O)OC(C)(C)C)(C)C JLHUENQHQNAMIR-CERRFVOPSA-N 0.000 description 34
- KNEJKPHKAGXIKD-UHFFFAOYSA-N CC(C=C1)=CC=C1S(OCCCNC(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)(=O)=O Chemical compound CC(C=C1)=CC=C1S(OCCCNC(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)(=O)=O KNEJKPHKAGXIKD-UHFFFAOYSA-N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000003921 oil Substances 0.000 description 27
- 235000019198 oils Nutrition 0.000 description 27
- 239000000376 reactant Substances 0.000 description 27
- 239000007821 HATU Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 23
- 239000003480 eluent Substances 0.000 description 22
- 239000000377 silicon dioxide Substances 0.000 description 22
- VIZXDTKPCYVSLL-SJORKVTESA-N tert-butyl (2s,4r)-4-hydroxy-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carboxylate Chemical compound N1=CSC(C=2C=CC(CNC(=O)[C@H]3N(C[C@H](O)C3)C(=O)OC(C)(C)C)=CC=2)=C1C VIZXDTKPCYVSLL-SJORKVTESA-N 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 19
- CRAUTELYXAAAPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione Chemical compound O=C1C=2C(F)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O CRAUTELYXAAAPW-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 18
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 18
- 108010026668 snake venom protein C activator Proteins 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000004481 post-translational protein modification Effects 0.000 description 16
- 239000000725 suspension Substances 0.000 description 15
- 239000003643 water by type Substances 0.000 description 15
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 14
- YGMDVFGZSZSJNZ-UHFFFAOYSA-N 4-[(2-chloro-5-fluoropyrimidin-4-yl)amino]-n-(2-chlorophenyl)benzamide Chemical compound FC1=CN=C(Cl)N=C1NC1=CC=C(C(=O)NC=2C(=CC=CC=2)Cl)C=C1 YGMDVFGZSZSJNZ-UHFFFAOYSA-N 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 241000400611 Eucalyptus deanei Species 0.000 description 12
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 11
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 11
- 125000005647 linker group Chemical group 0.000 description 11
- 102000015367 CRBN Human genes 0.000 description 10
- 229910004298 SiO 2 Inorganic materials 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- GXSQWRDYEMYDPB-UHFFFAOYSA-N 2-[4-[[4-[4-[(2-chlorophenyl)carbamoyl]anilino]-5-fluoropyrimidin-2-yl]amino]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1NC1=NC=C(F)C(NC=2C=CC(=CC=2)C(=O)NC=2C(=CC=CC=2)Cl)=N1 GXSQWRDYEMYDPB-UHFFFAOYSA-N 0.000 description 9
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 229910001873 dinitrogen Inorganic materials 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- QNLCWFKBLGSPME-DFQHDRSWSA-N (2S,4R)-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide hydrochloride Chemical compound [Cl-].O[C@@H]1C[C@H]([NH2+]C1)C(NCC1=CC=C(C=C1)C1=C(N=CS1)C)=O QNLCWFKBLGSPME-DFQHDRSWSA-N 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 7
- 229950009447 alisertib Drugs 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- ZMSXIPRVNDRUAW-UHFFFAOYSA-N 4-amino-n-(2-chlorophenyl)benzamide Chemical compound C1=CC(N)=CC=C1C(=O)NC1=CC=CC=C1Cl ZMSXIPRVNDRUAW-UHFFFAOYSA-N 0.000 description 5
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 5
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 4
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- LTKULTUWDIUMNO-UHFFFAOYSA-N n-(2-chlorophenyl)-4-nitrobenzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)NC1=CC=CC=C1Cl LTKULTUWDIUMNO-UHFFFAOYSA-N 0.000 description 4
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 4
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- QPPCMLRJKDOMIU-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-[3-(hydroxymethyl)pyrrolidin-1-yl]isoindole-1,3-dione Chemical compound OCC(CC1)CN1C(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O QPPCMLRJKDOMIU-UHFFFAOYSA-N 0.000 description 3
- PBGMRXNTLPSDNR-UHFFFAOYSA-N 4-(6-aminohexylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione hydrochloride Chemical compound Cl.NCCCCCCNc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12 PBGMRXNTLPSDNR-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000003989 Aurora kinases Human genes 0.000 description 3
- 108090000433 Aurora kinases Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- VGACRFNIXBHAHB-UHFFFAOYSA-N benzyl 4-piperidin-4-ylpiperazine-1-carboxylate Chemical compound C1CN(C2CCNCC2)CCN1C(=O)OCC1=CC=CC=C1 VGACRFNIXBHAHB-UHFFFAOYSA-N 0.000 description 3
- 210000003793 centrosome Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000011345 viscous material Substances 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 2
- VESILCAPQNJVEI-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(3-hydroxypropylamino)isoindole-1,3-dione Chemical compound OCCCNC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 VESILCAPQNJVEI-UHFFFAOYSA-N 0.000 description 2
- UJYKSURCHUDDSI-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(6-hydroxyhexylamino)isoindole-1,3-dione Chemical compound OCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O UJYKSURCHUDDSI-UHFFFAOYSA-N 0.000 description 2
- KPOXGUYDNJAFIX-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(8-hydroxyoctylamino)isoindole-1,3-dione Chemical compound OCCCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O KPOXGUYDNJAFIX-UHFFFAOYSA-N 0.000 description 2
- JNLDRGWQOAKHAY-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-(3-piperazin-1-ylpropylamino)isoindole-1,3-dione Chemical compound C1CC(N2C(=O)C3=CC(NCCCN4CCNCC4)=CC=C3C2=O)C(=O)NC1=O JNLDRGWQOAKHAY-UHFFFAOYSA-N 0.000 description 2
- CSEWAUGPAQPMDC-UHFFFAOYSA-N 2-(4-aminophenyl)acetic acid Chemical compound NC1=CC=C(CC(O)=O)C=C1 CSEWAUGPAQPMDC-UHFFFAOYSA-N 0.000 description 2
- ZSZCXAOQVBEPME-UHFFFAOYSA-N 2-(4-bromophenyl)ethanamine Chemical compound NCCC1=CC=C(Br)C=C1 ZSZCXAOQVBEPME-UHFFFAOYSA-N 0.000 description 2
- ZVWIXIGBWIEDFO-UHFFFAOYSA-N 2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetic acid Chemical compound O=C1C=2C(OCC(=O)O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O ZVWIXIGBWIEDFO-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 2
- DMUXSGAKEXSNGN-UHFFFAOYSA-N 2-ethyloctanoic acid Chemical compound CCCCCCC(CC)C(O)=O DMUXSGAKEXSNGN-UHFFFAOYSA-N 0.000 description 2
- GHBYNMXBNLSPBE-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)propan-1-amine Chemical compound C1CC(CCCN)CCN1CC1=CC=CC=C1 GHBYNMXBNLSPBE-UHFFFAOYSA-N 0.000 description 2
- IHRWMVVXSQATHL-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)propan-1-ol Chemical compound C1CC(CCCO)CCN1CC1=CC=CC=C1 IHRWMVVXSQATHL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- PAOHMIPLGDOHBB-UHFFFAOYSA-M 3-cyanopropyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCC#N)C1=CC=CC=C1 PAOHMIPLGDOHBB-UHFFFAOYSA-M 0.000 description 2
- FKHQERIJXCRFNE-UHFFFAOYSA-N 4-(10-aminodecylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C1=CC2=C(C(=C1)NCCCCCCCCCCN)C(=O)N(C2=O)C1CCC(=O)NC1=O FKHQERIJXCRFNE-UHFFFAOYSA-N 0.000 description 2
- KMGOFKGAYSFPGS-UHFFFAOYSA-N 4-(4-aminobutylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound NCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O KMGOFKGAYSFPGS-UHFFFAOYSA-N 0.000 description 2
- REUDLMVWBUGLDA-UHFFFAOYSA-N 4-(4-methyl-1,3-thiazol-5-yl)benzonitrile Chemical compound N1=CSC(C=2C=CC(=CC=2)C#N)=C1C REUDLMVWBUGLDA-UHFFFAOYSA-N 0.000 description 2
- YVIZBYPPHMBVPA-UHFFFAOYSA-N 4-(8-aminooctylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound NCCCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O YVIZBYPPHMBVPA-UHFFFAOYSA-N 0.000 description 2
- JEKQYPUPJKRHRM-UHFFFAOYSA-N 4-(9-aminononylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCCCCCCCCN JEKQYPUPJKRHRM-UHFFFAOYSA-N 0.000 description 2
- BSRCKYKLTKOXHB-UHFFFAOYSA-N 6-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]hexyl 4-methylbenzenesulfonate Chemical compound CC(C=C1)=CC=C1S(OCCCCCCNC(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)(=O)=O BSRCKYKLTKOXHB-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- XYIRCJTXTOSXMD-UHFFFAOYSA-N C(C1=CC=CC=C1)N1CCC(CC1)CCCN1C(C=2C(C1=O)=CC=CC=2)=O Chemical compound C(C1=CC=CC=C1)N1CCC(CC1)CCCN1C(C=2C(C1=O)=CC=CC=2)=O XYIRCJTXTOSXMD-UHFFFAOYSA-N 0.000 description 2
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 2
- JCGASCATZYPJRL-UHFFFAOYSA-N C1CC(N2C(=O)C3=C(C(NCCCCCNC(=O)OC(C)(C)C)=CC=C3)C2=O)C(=O)NC1=O Chemical compound C1CC(N2C(=O)C3=C(C(NCCCCCNC(=O)OC(C)(C)C)=CC=C3)C2=O)C(=O)NC1=O JCGASCATZYPJRL-UHFFFAOYSA-N 0.000 description 2
- BJUCXLVKDUDIRF-UHFFFAOYSA-N CC(C=C1)=CC=C1S(OCCCCCNC(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)(=O)=O Chemical compound CC(C=C1)=CC=C1S(OCCCCCNC(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)(=O)=O BJUCXLVKDUDIRF-UHFFFAOYSA-N 0.000 description 2
- VOBYUHDUTMVDRP-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCCCCCCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCCCCCCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O VOBYUHDUTMVDRP-UHFFFAOYSA-N 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 description 2
- 108010003751 Elongin Proteins 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- BVTLQQPLXRAFBQ-UHFFFAOYSA-N NCCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O Chemical compound NCCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O BVTLQQPLXRAFBQ-UHFFFAOYSA-N 0.000 description 2
- LPILBSGWFJLZPU-UHFFFAOYSA-N NCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O Chemical compound NCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O LPILBSGWFJLZPU-UHFFFAOYSA-N 0.000 description 2
- GLENDMWZMABWHU-UHFFFAOYSA-N NCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O Chemical compound NCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O GLENDMWZMABWHU-UHFFFAOYSA-N 0.000 description 2
- VNFWYVNPXMSMPZ-UHFFFAOYSA-N O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2NCC1CCNCC1 Chemical compound O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2NCC1CCNCC1 VNFWYVNPXMSMPZ-UHFFFAOYSA-N 0.000 description 2
- DTZWRPGSPVQULU-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCCO)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCCO)=O)=O DTZWRPGSPVQULU-UHFFFAOYSA-N 0.000 description 2
- XLIYSFOJKXMZQU-UHFFFAOYSA-N O=CC(C1)CN1C(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O Chemical compound O=CC(C1)CN1C(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O XLIYSFOJKXMZQU-UHFFFAOYSA-N 0.000 description 2
- BCJQVXQNBCZOHZ-UHFFFAOYSA-N OCC(C1)CN1C(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O Chemical compound OCC(C1)CN1C(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O BCJQVXQNBCZOHZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- PCZXZPOWHWJXDZ-UHFFFAOYSA-N [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methanamine Chemical compound N1=CSC(C=2C=CC(CN)=CC=2)=C1C PCZXZPOWHWJXDZ-UHFFFAOYSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 239000005441 aurora Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- RCKOYWNBAWVUQO-UHFFFAOYSA-N benzyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate Chemical compound N1CCC(CC1)CN1CCN(CC1)C(=O)OCC1=CC=CC=C1 RCKOYWNBAWVUQO-UHFFFAOYSA-N 0.000 description 2
- AWXFBUDOYXNHHK-UHFFFAOYSA-N benzyl 4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1CCN(C(=O)OCC=2C=CC=CC=2)CC1 AWXFBUDOYXNHHK-UHFFFAOYSA-N 0.000 description 2
- AQOHDRGIHCDBIV-UHFFFAOYSA-N benzyl 4-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methyl]piperazine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CN1CCN(CC1)C(=O)OCC1=CC=CC=C1 AQOHDRGIHCDBIV-UHFFFAOYSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 2
- PQEPCBUBKRUREA-UHFFFAOYSA-N but-3-ynylazanium;chloride Chemical compound Cl.NCCC#C PQEPCBUBKRUREA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- CSKSDAVTCKIENY-UHFFFAOYSA-N hydron;pyrrolidine-2-carboxamide;chloride Chemical compound Cl.NC(=O)C1CCCN1 CSKSDAVTCKIENY-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000006824 pyrimidine synthesis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 2
- 239000011755 sodium-L-ascorbate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- SBNNKCCXJSOWRV-UHFFFAOYSA-N tert-butyl 2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)OC(C)(C)C)=O)=O SBNNKCCXJSOWRV-UHFFFAOYSA-N 0.000 description 2
- ARXILKDHBYZMHT-UHFFFAOYSA-N tert-butyl 3-(4-aminobutyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(CCCCN)C1 ARXILKDHBYZMHT-UHFFFAOYSA-N 0.000 description 2
- BMRCCSNPULOUQA-UHFFFAOYSA-N tert-butyl 3-(4-aminobutyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCCCN)C1 BMRCCSNPULOUQA-UHFFFAOYSA-N 0.000 description 2
- MYIJXYLTQWCASN-UHFFFAOYSA-N tert-butyl N-[6-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]hexyl]carbamate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCCCNC(OC(C)(C)C)=O)=O)=O MYIJXYLTQWCASN-UHFFFAOYSA-N 0.000 description 2
- ZMFYRVRSANNVMP-UHFFFAOYSA-N tert-butyl N-[8-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]octyl]carbamate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCCCCCNC(OC(C)(C)C)=O)=O)=O ZMFYRVRSANNVMP-UHFFFAOYSA-N 0.000 description 2
- BCVMKVMKZSEQIX-UHFFFAOYSA-N tert-butyl n-(3-piperidin-4-ylpropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCC1CCNCC1 BCVMKVMKZSEQIX-UHFFFAOYSA-N 0.000 description 2
- RVZPDKXEHIRFPM-UHFFFAOYSA-N tert-butyl n-(6-aminohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCN RVZPDKXEHIRFPM-UHFFFAOYSA-N 0.000 description 2
- MRQBIMZMDWOQLF-UHFFFAOYSA-N tert-butyl n-[2-(4-bromophenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=CC=C(Br)C=C1 MRQBIMZMDWOQLF-UHFFFAOYSA-N 0.000 description 2
- OCUICOFGFQENAS-UHFFFAOYSA-N tert-butyl n-[2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCOCCN OCUICOFGFQENAS-UHFFFAOYSA-N 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MHFUWOIXNMZFIW-WNQIDUERSA-N (2s)-2-hydroxypropanoic acid;n-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 MHFUWOIXNMZFIW-WNQIDUERSA-N 0.000 description 1
- LRFZIPCTFBPFLX-SSDOTTSWSA-N (2s)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C(C)(C)C LRFZIPCTFBPFLX-SSDOTTSWSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
- UWIONISYGOCHGC-UHFFFAOYSA-N 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]pyrrolidine-3-carbaldehyde Chemical compound O=CC(CC1)CN1C(C=CC=C1C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O UWIONISYGOCHGC-UHFFFAOYSA-N 0.000 description 1
- UAYWVCDANGRKND-UHFFFAOYSA-N 1-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide hydrochloride Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)C3CCCN3O.Cl UAYWVCDANGRKND-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- ZULPPTNGMMHCIK-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(4-piperazin-1-ylbutylamino)isoindole-1,3-dione Chemical compound C1N(CCNC1)CCCCNC1=C2C(=CC=C1)C(=O)N(C1C(=O)NC(=O)CC1)C2=O ZULPPTNGMMHCIK-UHFFFAOYSA-N 0.000 description 1
- XFCIZDKNHGXYIZ-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[4-(piperazin-1-ylmethyl)piperidin-1-yl]isoindole-1,3-dione Chemical compound O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC(=CC=C12)N1CCC(CN2CCNCC2)CC1 XFCIZDKNHGXYIZ-UHFFFAOYSA-N 0.000 description 1
- GFCKACFUYUKAPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-piperazin-1-ylisoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N1CCNCC1)=O)=O GFCKACFUYUKAPW-UHFFFAOYSA-N 0.000 description 1
- SURCGQGDUADKBL-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(NCCO)C2=O)=O)=C3C2=CC=CC3=C1 SURCGQGDUADKBL-UHFFFAOYSA-N 0.000 description 1
- MFHFWRBXPQDZSA-UHFFFAOYSA-N 2-(4-bromophenyl)acetonitrile Chemical compound BrC1=CC=C(CC#N)C=C1 MFHFWRBXPQDZSA-UHFFFAOYSA-N 0.000 description 1
- LUPDLBROICENPT-UHFFFAOYSA-N 2-azidoethanamine;hydrochloride Chemical compound Cl.NCCN=[N+]=[N-] LUPDLBROICENPT-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- YIPVUXAMZQBALD-UHFFFAOYSA-N 3-azidopropanoic acid Chemical compound OC(=O)CCN=[N+]=[N-] YIPVUXAMZQBALD-UHFFFAOYSA-N 0.000 description 1
- DBIMLJDSPUCGGY-UHFFFAOYSA-N 3-piperidin-4-ylpropan-1-ol Chemical compound OCCCC1CCNCC1 DBIMLJDSPUCGGY-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- FQNYDLNLHXYZSO-UHFFFAOYSA-N 4-(2-azidoethylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCN=[N+]=[N-])=O)=O FQNYDLNLHXYZSO-UHFFFAOYSA-N 0.000 description 1
- LCVIRAZGMYMNNT-UHFFFAOYSA-N 4-(3-chloro-2-fluorophenoxy)-1-[[6-(2-thiazolylamino)-2-pyridinyl]methyl]-1-cyclohexanecarboxylic acid Chemical compound C1CC(OC=2C(=C(Cl)C=CC=2)F)CCC1(C(=O)O)CC(N=1)=CC=CC=1NC1=NC=CS1 LCVIRAZGMYMNNT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VUTCFPKPHCMKEA-UHFFFAOYSA-N 4-(6-aminohexylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione 2,2,2-trifluoroacetic acid Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCCCCCN.C(=O)(C(F)(F)F)O VUTCFPKPHCMKEA-UHFFFAOYSA-N 0.000 description 1
- XSGJJCWXQKDYKP-UHFFFAOYSA-N 4-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methyl]piperazine-1-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1CCN(C(O)=O)CC1 XSGJJCWXQKDYKP-UHFFFAOYSA-N 0.000 description 1
- HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
- ROFGDCOBISHGRK-UHFFFAOYSA-N 4-fluoroisoindole-1,3-dione Chemical compound FC1=CC=CC2=C1C(=O)NC2=O ROFGDCOBISHGRK-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- FPRZYWCRQHFPSX-UHFFFAOYSA-N 8-[(2-methylpropan-2-yl)oxycarbonylamino]octanoic acid Chemical compound CC(C)(C)OC(=O)NCCCCCCCC(O)=O FPRZYWCRQHFPSX-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101000810330 Arabidopsis thaliana Eukaryotic translation initiation factor 3 subunit E Proteins 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- KJDJOCQCMNPOBZ-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O Chemical compound CC(C)(C)OC(=O)NCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O KJDJOCQCMNPOBZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DQZGBGLZCXHVCB-UHFFFAOYSA-N Cc1ncsc1-c1ccc(CNC(=O)C2CC(O)CN2)cc1 Chemical compound Cc1ncsc1-c1ccc(CNC(=O)C2CC(O)CN2)cc1 DQZGBGLZCXHVCB-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102100039193 Cullin-2 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000012698 DDB1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 description 1
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101710095156 E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004662 Elongin Human genes 0.000 description 1
- 102100030209 Elongin-B Human genes 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 1
- CDVHPHYZHWBSRZ-UHFFFAOYSA-N FC(C(=O)O)(F)F.C1(NC(C2=CC=CC=C12)=O)=O Chemical compound FC(C(=O)O)(F)F.C1(NC(C2=CC=CC=C12)=O)=O CDVHPHYZHWBSRZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000746072 Homo sapiens Cullin-2 Proteins 0.000 description 1
- 101001111722 Homo sapiens E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 101000574654 Homo sapiens GTP-binding protein Rit1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- OUBORTRIKPEZMG-UHFFFAOYSA-N INT-2 Chemical compound Nc1c(ncn1-c1ccc(F)cc1)C(=N)C#N OUBORTRIKPEZMG-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 1
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- GCIKSSRWRFVXBI-UHFFFAOYSA-N N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 GCIKSSRWRFVXBI-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- BRZZEGGDXBDFHH-UHFFFAOYSA-N O=C(C(C1=C2)=CC=C2N(CC2)CCC2N2CCNCC2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2N(CC2)CCC2N2CCNCC2)N(C(CCC(N2)=O)C2=O)C1=O BRZZEGGDXBDFHH-UHFFFAOYSA-N 0.000 description 1
- WWTZYIVSEBKFOX-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)N1CCC(CC1)CN1CCNCC1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)N1CCC(CC1)CN1CCNCC1)=O)=O WWTZYIVSEBKFOX-UHFFFAOYSA-N 0.000 description 1
- OYPNLZMEXLFKLB-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCNC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCNC(OC(C)(C)C)=O)=O)=O OYPNLZMEXLFKLB-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- BXHRXLMCYSZSIY-STECZYCISA-N Pro-Tyr-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1)C(O)=O BXHRXLMCYSZSIY-STECZYCISA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100032783 Protein cereblon Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101710178916 RING-box protein 1 Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 229910020175 SiOH Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000053200 Von Hippel-Lindau Tumor Suppressor Human genes 0.000 description 1
- 108700031765 Von Hippel-Lindau Tumor Suppressor Proteins 0.000 description 1
- 101001060278 Xenopus laevis Fibroblast growth factor 3 Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BMBANPOHPFKVTA-UHFFFAOYSA-N benzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC(=O)C1=CC=CC=C1 BMBANPOHPFKVTA-UHFFFAOYSA-N 0.000 description 1
- UTXVJZQAALXMBZ-UHFFFAOYSA-N benzyl N-(9-aminononyl)carbamate Chemical compound C(C1=CC=CC=C1)OC(NCCCCCCCCCN)=O UTXVJZQAALXMBZ-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- ISUIGFYCBBIILY-UHFFFAOYSA-N benzyl n-(7-aminoheptyl)carbamate Chemical compound NCCCCCCCNC(=O)OCC1=CC=CC=C1 ISUIGFYCBBIILY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 101150077768 ddb1 gene Proteins 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-M fluoroacetate Chemical compound [O-]C(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-M 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- SXJVFQLYZSNZBT-UHFFFAOYSA-N nonane-1,9-diamine Chemical compound NCCCCCCCCCN SXJVFQLYZSNZBT-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical compound [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000022131 polyp of large intestine Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- QOTUIIJRVXKSJU-UHFFFAOYSA-N pyrrolidin-3-ylmethanol Chemical compound OCC1CCNC1 QOTUIIJRVXKSJU-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- KDOLGICVVPEEHO-UHFFFAOYSA-N pyrrolidine-3-carbaldehyde Chemical compound O=CC1CCNC1 KDOLGICVVPEEHO-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ONEXXCWDECZYMU-UHFFFAOYSA-N tert-butyl 2-(aminomethyl)-7-azaspiro[3.5]nonane-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CC(CN)C1 ONEXXCWDECZYMU-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N tert-butyl 3-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C1 VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- JSOMVCDXPUXKIC-UHFFFAOYSA-N tert-butyl 3-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C1 JSOMVCDXPUXKIC-UHFFFAOYSA-N 0.000 description 1
- QZYIDMYWRACBRQ-UHFFFAOYSA-N tert-butyl 4-(3-aminopropyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCCN)CC1 QZYIDMYWRACBRQ-UHFFFAOYSA-N 0.000 description 1
- UYZVZLYOXDJHPR-UHFFFAOYSA-N tert-butyl 4-(piperazin-1-ylmethyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1CCNCC1 UYZVZLYOXDJHPR-UHFFFAOYSA-N 0.000 description 1
- JYUQEWCJWDGCRX-UHFFFAOYSA-N tert-butyl 4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)CC1 JYUQEWCJWDGCRX-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- AIJRFEVPPVOMRI-UHFFFAOYSA-N tert-butyl N-[10-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]decyl]carbamate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCCCCCCCNC(OC(C)(C)C)=O)=O)=O AIJRFEVPPVOMRI-UHFFFAOYSA-N 0.000 description 1
- RSAPJHYIFKJREV-UHFFFAOYSA-N tert-butyl n-(10-aminodecyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCCCCCN RSAPJHYIFKJREV-UHFFFAOYSA-N 0.000 description 1
- RQRMFFGCUUGYPC-UHFFFAOYSA-N tert-butyl n-(2-piperidin-4-ylethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCC1CCNCC1 RQRMFFGCUUGYPC-UHFFFAOYSA-N 0.000 description 1
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
- ZFQWJXFJJZUVPI-UHFFFAOYSA-N tert-butyl n-(4-aminobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCN ZFQWJXFJJZUVPI-UHFFFAOYSA-N 0.000 description 1
- DPLOGSUBQDREOU-UHFFFAOYSA-N tert-butyl n-(5-aminopentyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCN DPLOGSUBQDREOU-UHFFFAOYSA-N 0.000 description 1
- BEHVGNKIRNVBPF-UHFFFAOYSA-N tert-butyl n-(8-aminooctyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCCCN BEHVGNKIRNVBPF-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to a compound for inducing selective degradation of AURKA and a pharmaceutical composition for preventing or treating cancer comprising the compound as an active ingredient.
- Aurora kinase is a kinase belonging to serine/threonine kinases that regulate cell division.
- the human three structural isoforms of Aurora kinase (Aurora A, Aurora B, Aurora C) show distinct functions and different subcellular distributions during cell mitosis and show different functions.
- Aurora kinase A (AURKA) is located in the centrosome of interphase cells, is involved in centrosome maturation and bipolar spindle formation, and its activity is known to be highest in the G2/M phase.
- AURKA is also a chromosomal passenger protein kinase and regulates phosphorylation of histone H3 at serine 10.
- AURKA Overexpression of AURKA causes hyperphosphorylation of normal cell division targets and aberrant phosphorylation of cytoplasmic targets, resulting in chromosomal instability, oncogenic transformation, tumor progression and development of anticancer drug resistance. Therefore, overexpression of AURKA is often observed in various cancer cells such as colon, pancreas, breast, lung, thyroid cancer and leukemia. Recently, a number of noteworthy reports have demonstrated that aurora kinase is an attractive anti-cancer drug target. Inhibition of AURKA stops mitosis by forming a monopolar spindle during mitosis through abnormal formation of spindle and immature centrosome formation.
- AURKA inhibitors targeting cancer treatment various compounds are under clinical trials as AURKA inhibitors targeting cancer treatment, and known AURKA inhibitors are VE465, tozasertib (VX-680), MK-0457, MK-5108, Ali Alisertib (MLN-8237), LY3295668, etc. exist.
- AURKA inhibitors are VE465, tozasertib (VX-680), MK-0457, MK-5108, Ali Alisertib (MLN-8237), LY3295668, etc. exist.
- VX-680 tozasertib
- MK-0457 MK-5108
- MK-5108 Ali Alisertib
- LY3295668 Ali Alisertib
- PROTAC Protein-based platform technology capable of inducing proteolysis of a target protein in vivo.
- PROTAC is a bifunctional compound in which a ligand molecule that binds to a disease-related target protein and an E3 ubiquitin ligase binding moiety are connected by a chemical linker. Theoretically, PROTAC compounds can induce degradation of target proteins by positioning them near the E3 ubiquitin ligase.
- PROTAC can selectively bind to a target protein by a ligand molecule that binds to the target protein (eg AURKA), and the E3 ubiquitin ligase by the E3 ubiquitin ligase binding moiety. Recruitment to the target protein can lead to ubiquitination and subsequent degradation of the target protein via the proteasome.
- a ligand molecule that binds to the target protein eg AURKA
- E3 ubiquitin ligase by the E3 ubiquitin ligase binding moiety.
- Recruitment to the target protein can lead to ubiquitination and subsequent degradation of the target protein via the proteasome.
- non-patent document 1 [Adhikari, Bikash, et al. Nature chemical biology 16.11 (2020): 1179-1188] and non-patent literature 2 [Wang, Richard, et al. Communications biology 4.1 (2021): 1-15.] discloses Alisertib (MLN-8237), known as an AURKA inhibitor, and this functional compound in which a binding moiety for E3 ubiquitin ligase is connected by a chemical linker.
- the PROTAC compound disclosed in Non-Patent Document 1 was confirmed to have AURKA resolution of 60% or less, and the PROTAC compound disclosed in Non-Patent Document 2 was confirmed to have AURKA resolution of 50% or less, resulting in a PROTAC compound having improved AURKA resolution and selectivity. It is still in demand.
- the inventors of the present invention have come to complete the present invention, noting that if a compound capable of effectively inducing selective degradation of AURKA can be developed, it can be applied to cancer treatment using AURKA as a target.
- the present invention has been made in consideration of the above problems, and an object of the present invention is to provide a compound that induces selective degradation of AURKA.
- Another object of the present invention is to provide a method for producing a compound inducing selective degradation of AURKA.
- Another object of the present invention is to provide a use of a compound inducing selective degradation of AURKA.
- the present invention provides a novel compound that induces degradation or selective degradation of AURKA (Aurora kinase A). Specifically, the present invention provides a bifunctional compound in which an AURKA binding moiety and an E3 ubiquitin ligase binding moiety are connected by a chemical linker.
- a compound represented by Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is provided:
- ULM is an E3 ubiquitin ligase binding moiety represented by Formula A or Formula B below,
- X 1 is a single bond, -CH 2 -, -NH-, -O-, -CH 2 CH 2 -, -CC- -CO-, -COO-, -NHCO- or -CONH-;
- X 3 is hydrogen
- X 4 is hydrogen, halogen, C 1-6 alkyl, CN, NH 2 , NO 2 , OH, COH, COOH or CF 3 ⁇
- n is an integer from 1 to 3;
- Y 1 is hydrogen or C 1-3 alkyl ⁇
- PTM is an AURKA binding moiety represented by Formula II below,
- R 1 and R 2 are each independently hydrogen, -NO 2 , -CN, -OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1- 6 thioalkoxy, C 3-6 cycloalkyl, C 3-6 heterocycloalkyl, C 3-6 heteroaryl, phenyl or halogen;
- R 3 is C 1-6 alkylene, -O-, -S-, -NH- , or a direct bond;
- Linker is a group that chemically connects ULM and PTM.
- the ULM is a CRBN E3 ubiquitin ligase binding moiety represented by Formula A above.
- CRBN means Cereblon E3 ubiquitin ligase.
- CRBN together with DDB1, Cul4A and ROC1 constitute the E3 ubiquitin ligase complex, where CRBN is the substrate recognition subunit of the complex.
- Some compounds capable of binding CRBN E3 ubiquitin ligase are known in the art.
- Ids immunomodulatory imide drugs
- the ULM may be an E3 ubiquitin ligase ligand represented by Formula A-1 below.
- X 3 is hydrogen.
- Chemical Formula A-1 may be selected from the group consisting of the following moieties.
- CRBN E3 ubiquitin ligase binding moiety Another example of a CRBN E3 ubiquitin ligase binding moiety according to the present invention is as follows (Burslem et al. 2018).
- the CRBN E3 ubiquitin ligase binding moiety of the present invention is as follows.
- X 2 may be -CO-, and X 3 may be H.
- ULM is a VHL E3 ubiquitin ligase binding moiety represented by Formula B above.
- VHL means von Hippel-Lindau tumor suppressor.
- VHL together with Elongin B, Elongin C, CUL2 and Rbx1 constitute the VCB E3 ubiquitin ligase complex, where VHL is the substrate recognition subunit of the complex.
- n may be an integer of 1 to 3, an integer of 1 to 2, or 1.
- in Formula B May be a 5-6 membered heterocycloalkyl or 5-6 membered heteroaryl ring containing at least one heteroatom selected from the group consisting of N, O and S, and specifically, the above is oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, oxadiazole, pyrrole, pyrrolidine, furan, dihydrofuran and tetrahydrofuran. It may be a heteroaryl ring, more specifically, the Can be a 5-membered heteroaryl ring containing N and S.
- Y 1 in Formula B may be C 1-3 alkyl. Specifically, Y 1 may be C 1 alkyl.
- Formula B may be selected from the group consisting of the following moieties.
- the PTM moiety that functions as a target protein ligand is the AURKA binding moiety represented by Formula II.
- Formula II constituting some moieties of the compound of Formula I according to the present invention can bind to the active site of AURKA alone.
- R 1 and R 2 are each independently F, Cl. It may be a halogen selected from the group consisting of Br and I. Specifically, R 1 may be Cl, and R 2 may be F.
- R 3 may be C 1 alkylene or a direct bond.
- the direct bond may mean a case in which R 3 is null.
- in Formula II may be a 4- to 10-membered heterocycloalkyl containing at least one heteroatom selected from the group consisting of N, O and S.
- the above May be a 4-9 membered, 4-9 membered, 5-membered, 6-membered or 9-membered heterocycloalkyl containing at least one N.
- the cycloalkyl or heterocycloalkyl refers to a non-aromatic monocyclic or multicyclic ring-based hydrocarbon ring, and as a polycyclic ring, a bridgehead, a fused ring, a spiro ring ( spiro).
- in Formula II may be a direct bond.
- the direct bond is may mean a case where is null.
- Formula II may be selected from the group consisting of the following moieties.
- R 1 , R 2 and R 3 are the same as defined in Formula II above.
- Formula II may be selected from the group consisting of the following moieties.
- Linker is a group that chemically connects ULM and PTM and is represented by the following formula L:
- L PTM is connected to It binds to the PTM moiety through
- L ULM and L PTM are each independently a single bond, -CH 2 -, -NH-, -O-, -CO-, -OCO-, -CONH-, -NHCO-, -O(CH) n CONH- ⁇
- n is an integer from 1 to 5 ⁇ , or a direct bond
- L INT is C 1-10 alkylene, -CH 2- , -NH-, -O(CH) n CONH- ⁇ wherein n is an integer from 1 to 5 ⁇ , -(CH 2 ) l O(CH 2 ) m O(CH 2 ) q - ⁇ Where l, m and q are independently integers from 1 to 5 ⁇ , -CHCH-, -CC-, -CH 2 CH 2 O-, -OCH 2 CH 2 -, - CH 2 CH 2 S-, -SCH 2 CH 2 -, -COO-, -CONH-, -NHCO-, And selected from the group consisting of a direct bond ⁇ where, is a ring selected from the group consisting of aryl, heteroaryl, 3-10 membered cycloalkyl, 4-10 membered heterocycloalkyl, 4-10 membered cycloalkenyl, and 4-10 membered heterocycloalkenyl ⁇ ;
- L ULM , L PTM and L INT are each independently selected from one or more of C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 heterocycloalkyl, halogen, hydroxy , amine, nitro, cyano or C 1-8 8 haloalkyl;
- p is an integer of 1 to 20, an integer of 1 to 10, an integer of 1 to 6, or an integer of 1 to 3;
- the cycloalkyl, heterocycloalkyl or heterocycloalkenyl means a non-aromatic monocyclic or multicyclic hydrocarbon ring, and as a polycyclic ring, a bridgehead, a fused ring ), and a double ring group such as spiro.
- L ULM , L PTM or in L INT A direct bond is L ULM , L PTM or This may mean that L INT is nothing (null).
- the linker is a linker included in compounds 1 to 38 shown in Table 1 below.
- the compound represented by Formula I is at least one compound selected from the group consisting of compounds 1 to 38 shown in Table 1 below, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. .
- a pharmaceutically acceptable salt is any organic acid or inorganic acid addition salt at a concentration that has an effective effect that is relatively non-toxic and harmless to patients and does not reduce the beneficial effects of the compound represented by formula (I) by side effects caused by otitis media. it means.
- the pharmaceutically acceptable salt may be hydrochloric acid, phosphoric acid, sulfuric acid, or nitric acid as an inorganic acid, and methanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, Benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, or hydroiodic acid. It may be, but is not limited to these.
- the compound represented by the above-mentioned formula (I), its stereoisomer or its pharmaceutically acceptable salt is synthesized in the organic chemistry field by known synthesis methods or transformation and derivatization techniques obvious to those skilled in the art. It can be prepared by the same reaction as 1 to 3.
- PTM, Linker and ULM are groups defined above or suitable derivatives thereof, and RG 1 , RG 2 , RG 2a , RG 2b , RG 3 , RG 3a , RG 3b and RG 4 are organic synthesis moieties containing suitable reactive groups capable of linking together the PROTAC compound intermediates represented by Formula I through the formation of covalent bonds in the field.
- the covalent bond formation is carried out through synthesis reactions such as amide formation, ester formation, carbamate formation, urea formation, ether formation, amine formation, and various carbon single bonds, double bonds, click chemistry, etc., depending on the specific reactive group. can be formed, but is not limited thereto.
- a variation of each step in the above reaction schemes may involve one or multiple synthetic steps. Isolation and purification of the product can be accomplished by standard procedures known to those skilled in the art of organic chemistry.
- the reactant indicated by PTM and the reactant indicated by ULM can be easily synthesized by a person skilled in the art by referring to literature known in the field of organic chemistry and the description of examples of the present invention.
- the present invention includes compounds of the form PTM-Linker-RG 3 or PTM-Linker 1-RG 2b corresponding to the reaction intermediate of formula (I).
- a composition for inducing decomposition of AURKA comprising the compound represented by Formula 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof is provided.
- Formula I is as defined above.
- the AURKA degradation-inducing PROTAC compound according to the present invention can degrade AURKA, which is the target protein, from the viewpoint of the mechanism of action, it achieves an excellent AURKA inhibitory effect even compared to conventional AURKA small molecule inhibitors that inhibit the simple activity of AURKA.
- composition comprising the compound represented by Formula 1, its stereoisomer or its pharmaceutically acceptable salt according to the present invention can be usefully used for the selective decomposition of AURKA.
- a pharmaceutical composition for preventing or treating AURKA-related diseases comprising the compound represented by Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- Formula I is as defined above.
- an AURKA-related disease refers to any disease or condition that can be treated, alleviated, delayed, inhibited, or prevented from inducing degradation or inhibiting the activity of AURKA.
- the AURKA-related disease may be cancer (malignant tumor) or benign tumor.
- the “cancer” includes all cancers that can exhibit preventive or therapeutic effects due to inhibition of AURKA activity, and may be solid cancer or hematological cancer.
- the cancer is squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous cell carcinoma of the lung, peritoneal cancer, skin cancer, skin or intraocular melanoma, rectal cancer, perianal cancer, esophageal cancer, small intestine cancer, endocrine cancer Adenocarcinoma, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, myelofibrosis, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver tumor, It may be one or more selected from the group consisting of breast cancer, colon cancer, colon
- the benign tumors include all benign tumors capable of exhibiting preventive or therapeutic efficacy due to inhibition of AURKA activity, such as benign tumors in a pre-cancerous stage, and may be solid tumors or hematological tumors.
- the tumor may be at least one selected from the group consisting of Barrett's esophagus, colorectal adenoma and polyp, breast fibroadenoma and cyst, single cell gammaglobulinopathy (MGUS), monoclonal lymphocytosis, etc., but is not limited thereto.
- a method for degrading AURKA protein by administering the compound represented by Formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof to a subject is provided.
- a method for degrading AURKA protein by administering the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof to a sample in vitro is provided.
- the sample may be cells, cell cultures, body fluids or tissues of mammals including humans, but is not limited thereto.
- a method for preventing or treating cancer comprising the step of administering the compound represented by Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof to a subject in need thereof .
- “individual” means a subject to be treated for a disease, and more specifically, means a mammal such as a human or non-human primate, mouse, dog, cat, horse, or cow.
- prevention refers to any activity that delays the progression of cancer by inhibiting the proliferation of tumors or cancer cells or inducing apoptosis of tumors or cancer cells by administering the pharmaceutical composition of the present invention.
- treatment refers to all activities that improve or beneficially change cancer by inhibiting proliferation of tumors or cancer cells or inducing apoptosis of tumors or cancer cells by administration of the pharmaceutical composition of the present invention, An attempt to obtain useful or desirable results, including clinical results.
- a useful or desirable clinical outcome, whether detectable or not, is alleviation or amelioration of one or more symptoms or conditions, reduction of disease extent, stabilization of disease state, inhibition of disease occurrence, inhibition of disease spread, delay or slowing of disease progression. , delay or slowing of disease onset, improvement or alleviation of disease state, and reduction (partial or total), but are not necessarily limited thereto.
- treatment may mean prolonging the survival of a patient beyond what would be predicted in the absence of treatment.
- treatment may refer to inhibition of disease progression, temporary slowing of disease progression, and more preferably relates to stopping the progression of a disease forever. In the present invention, it may mean improving the survival of patients by enhancing anticancer effects.
- the pharmaceutical composition of the present invention can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively. there is.
- Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the compound of the present invention, for example, starch, calcium carbonate, sucrose or lactose, It is prepared by mixing gelatin, etc.
- lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
- Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions.
- As a base for the suppository witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.
- the dosage of the pharmaceutical composition of the present invention will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration, and the judgment of the prescriber. Determination of dosage based on these factors is within the level of those skilled in the art, and generally dosages range from 0.0001 mg/kg/day to approximately 3000 mg/kg/day. A more preferred dosage is 0.1 mg/kg/day to 1000 mg/kg/day. Administration may be administered once a day, or may be administered in several divided doses. The dosage is not intended to limit the scope of the present invention in any way.
- the pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, and humans through various routes. All modes of administration are contemplated, eg oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebrovascular injection.
- the pharmaceutical composition for preventing or treating cancer may further include, in addition to the active ingredient, any compound or natural extract whose safety has already been verified and is known to have anticancer activity for enhancement and reinforcement of anticancer effect. there is.
- an anticancer adjuvant for cancer treatment comprising the compound represented by Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- anti-cancer adjuvant refers to a composition that synergistically increases the effect of anti-cancer treatment by preventing side effects caused by the anti-cancer agent when applied in parallel with treatment with an anti-cancer agent. Therefore, the adjuvant for treatment is an anticancer adjuvant and can be administered simultaneously or sequentially with an anticancer agent.
- Anticancer agents can be selected based on general principles that are considered when selecting an anticancer agent, such as the type of cancer cell, the rate of absorption of the anticancer agent (treatment period and route of administration of the anticancer agent), the location of the tumor, and the size of the tumor.
- the compound according to the present invention may exhibit an effect of inducing selective degradation of AURKA. Therefore, the compound according to the present invention can be usefully used for preventing or treating AURKA-related cancer.
- FIG. 1 is a Western blot image showing AURKA resolution and AURKA selectivity when the concentrations of example compounds are 0.1 ⁇ M and 1 ⁇ M
- Compounds 1 and 2 , 3, 11 and 13/ Figure 1b Compounds 4, 5, 12, 13, 14 and 30/ Figure 1c: Compounds 6, 7, 8, 9, 10/ Figure 1d: Compounds 15, 18, 19, 20 and 31 / Fig. 1e: Compounds 13, 16, 17 and 21/ Fig. 1f: Compounds 15, 22, 24, 32 and 33/ Fig. 1g: Intermediate 1, Compounds 13, 25, 26, 27 and 28/ Fig. 1h: Intermediate 1, Compounds 13, 35, 36, 37 and 38/ N. Control: Negative Control (no compound treatment)].
- Figure 2 is a Western blot image showing AURKA resolution in the case of low concentrations of 6 nM and 30 nM of example compounds
- Figure 2b Intermediate 1
- Figure 2c Compounds 2, 11, 14, 15 and 17/
- Figure 2d Compounds 15, 16, 18, 20 and 21
- Figure 2e Compounds 15, 26, 36 and 37/ N.
- Control Negative Control (untreated with compound)].
- Figure 3 is a Western blot image showing the AURKA resolution when the concentration of Alisertib-based PROTAC of Comparative Examples 1 to 3 is 0.1 ⁇ M and 1 ⁇ M [Fig. 3a: Comparative Example 1 / Fig. 3b: Comparative Example 2 / Fig. 3c: Comparative Example 3].
- FIG. 4 is a schematic diagram showing the principle of action of PROTAC.
- the present invention provides synthesis methods for compounds 1 to 38 shown in Table 1 below.
- the compounds of the present invention were purified and structurally analyzed according to the method below.
- HPLC data were obtained using 1260 Infinity II G1311B, G7111B or G6410B, 0.1% TFA in water (solvent A) and acetonitrile (solvent B) or 10 mM NH4HCO3 (solvent A) and acetonitrile in water (solvent B) or water.
- 0.0375% TFA (solvent A) and 0.01875% TFA in acetonitrile (solvent B) were used as mobile phases.
- Columns were X-Bridge C8 (150X4.6) mm, 3.5 ⁇ m, Atlantis dC18 (250X4.6) mm, 5 ⁇ m or Zobrax Eclipse Plus C18 (4.6X150)mm, 3.5um.
- Step 4 Synthesis of 4-((2-chloro-5-fluoropyrimidin-4-yl)amino)-N-(2-chlorophenyl)benzamide (INT-4)
- Step 6 tert-Butyl 4-(2-(4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino) Synthesis of phenyl) acetyl) piperazine-1-carboxylate (INT-6)
- Step 7 N-(2-chlorophenyl)-4-((5-fluoro-2-((4-(2-oxo-2-(piperazin-1-yl)ethyl)phenyl)amino)pyrimidine Synthesis of -4-yl)amino)benzamide 2,2,2-trifluoroacetate (UPP-L1)
- Step 4 Synthesis of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (5)
- Step 5 tert-Butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine Synthesis of -1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (6)
- Step 1 tert-butyl (2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) Synthesis of thoxy) ethoxy) ethyl) carbamate (2)
- Step 2 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3 -Synthesis of dione hydrochloride (3)
- Step 3 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy) Synthesis of ethoxy)ethyl)piperazine-1-carboxamide (Compound 1)
- Step 1 tert-butyl (6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)carbamate (2) synthesis of
- Step 2 4-((6-aminohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 2,2,2-trifluoroacetate Synthesis of (3)
- Step 3 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)piperazine-1-carboxyl Synthesis of mid (compound 2)
- Step 1 N-(but-3-yn-1-yl)-4-(2-(4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5- Synthesis of fluoropyrimidin-2-yl)amino)phenyl)acetyl)piperazine-1-carboxamide (2)
- Step 2 Synthesis of 4-((2-azidoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (4)
- Step 3 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(2-(1-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)- Synthesis of 1H-1,2,3-triazol-4-yl)ethyl)piperazine-1-carboxamide (Compound 3)
- Step 1 Synthesis of tert-butyl (2-(1-(2-cyanoethyl)piperidin-4-yl)ethyl)carbamate (2)
- Step 2 Synthesis of tert-butyl (2-(1-(3-aminopropyl)piperidin-4-yl)ethyl)carbamate (3)
- Step 3 tert-Butyl (2-(1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl Synthesis of )piperidin-4-yl)ethyl)carbamate (4)
- Step 4 4-((3-(4-(2-aminoethyl)piperidin-1-yl)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline Synthesis of -1,3-dione 2,2,2-trifluoroacetate (5)
- reaction mixture was concentrated under reduced pressure, and the residue was dissolved in a mixture of DCM/MeOH (1/1, 30 mL). Si-carbonate ( ⁇ 1 g) was added to the solution and stirred at 25 °C for 2 hours. The resin was filtered through celite and washed with methanol (25 mL). The filtrate was concentrated under reduced pressure to obtain the title compound (0.72 g, 100 % yield) as a greenish yellow gum.
- Step 5 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(2-(1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)p Synthesis of peridin-4-yl)ethyl)piperazine-1-carboxamide (Compound 4)
- Step 1 Synthesis of tert-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate (2)
- Step 2 Synthesis of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (3)
- Step 3 tert-Butyl (2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) Synthesis of oxy)acetamido)ethoxy)ethoxy)ethyl)carbamate (4)
- Step 4 N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-di Synthesis of oxoisoindolin-4-yl)oxy)acetamide 2,2,2-trifluoroacetate (5)
- Step 5 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy) Synthesis of acetamido)ethoxy)ethoxy)ethyl)piperazine-1-carboxamide (Compound 5)
- Step 1 tert-butyl (2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazole-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl)carbamate (2) synthesis of
- Step 2 (2S,4R)-1-((S)-2-(2-(2-(2-aminoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4- Synthesis of hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (3)
- Step 3 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl) benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperazine-1-carboxyl Synthesis of mid (compound 6)
- Step 1 tert-Butyl (8-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl ) Synthesis of pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl) amino)-8-oxooctyl) carbamate (2)
- Step 2 (2S,4R)-1-((S)-2-(8-aminooctaneamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthia Synthesis of sol-5-yl) benzyl) pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (3)
- Step 3 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(8-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)p Synthesis of Rolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-8-oxooctyl)piperazine-1-carboxamide (Compound 7)
- reaction process was observed by LCMS. After completion of the reaction, the reaction mixture was diluted with cold water (20 mL) and extracted with EtOAc (2 X 20 mL). The combined organic phases were washed with 10% NaHCO 3 (30 mL) solution and brine (2 X 20 mL). The obtained organic phase was dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The obtained residue was purified by flash column chromatography (100-200 mesh) and eluted with 3-5% MeOH/DCM to give the titled compound (650 mg, 56.8 % yield) as an off-white solid.
- Step 3 (2S,4R)-1-((S)-2-(3-(4-(3-aminopropyl)phenyl)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy Synthesis of -N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (4)
- the reactant was filtered through celite, and the residue obtained by concentration under reduced pressure was diluted with ammonium hydroxide solution (20 mL) and extracted with DCM (2 X 20 mL). The organic phase was dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give the titled compound (202 mg, 40.0 % yield) as pale brown gum.
- Step 4 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(3-(4-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl) benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)phenyl)propyl)piperazine-1-carboxamide ( Synthesis of compound 8)
- Step 1 N-(but-3-yn-1-yl)-4-(2-(4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5- Synthesis of fluoropyrimidin-2-yl)amino)phenyl)acetyl)piperazine-1-carboxamide (2)
- Step 2 (2S,4R)-1-((S)-2-(3-azidopropanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-) Synthesis of methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (4)
- Step 3 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(2-(1-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl) Benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)-1H-1,2,3-triazole-4 Synthesis of -yl)ethyl)piperazine-1-carboxamide (Compound 9)
- Step 3 Synthesis of 2-(3-(1-benzylpiperidin-4-yl)propyl)isoindoline-1,3-dione (4)
- Step 7 Synthesis of ethyl 3-(4-(3-((tert-butoxycarbonyl)amino)propyl)piperidin-1-yl)propanoate (8)
- Step 8 Synthesis of 3-(4-(3-((tert-butoxycarbonyl)amino)propyl)piperidin-1-yl)propanoic acid (9)
- Step 9 tert-Butyl (3-(1-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazole-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)piperidin-4-yl)propyl)carba Synthesis of Mate (10)
- the reaction mixture was stirred at 25 °C for 3 hours and the reaction process was observed by UPLC-MS. After completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 X 20 mL). The combined organic phases were washed with 10% NaHCO 3 solution (20 mL), dried over Na 2 SO 4 and concentrated under reduced pressure. The obtained compound was purified by flash column chromatography and eluted with 3-5% MeOH/CH 2 Cl 2 . The target compartment was concentrated under reduced pressure to obtain the title compound (326 mg, 43.9 % yield) as a brown gum.
- Step 10 (2S,4R)-1-((S)-2-(3-(4-(3-aminopropyl)piperidin-1-yl)propanamido)-3,3-dimethylbutanoyl Synthesis of )-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate (11)
- Step 11 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(3-(1-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl) Benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)piperidin-4-yl)propyl)piperazine- Synthesis of 1-carboxamide (Compound 10)
- Step 3 Synthesis of tert-butyl (E/Z)-(4-(2-cyanovinyl)phenethyl)carbamate (4)
- Step 4 Synthesis of tert-butyl (4-(3-aminopropyl)phenethyl)carbamate (5)
- Step 6 4-((3-(4-(2-aminoethyl)phenyl)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Synthesis of 2,2,2-trifluoroacetate (7)
- Step 7 4-(2-(4-((4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetyl )-N-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)phenethyl)pipeline Synthesis of Razine-1-Carboxamide (Compound 11)
- the reactant was diluted with water (30 mL), and the compound was sequentially extracted with DCM (10 mL) and a mixture of THF and DCM (2 X 20 mL) (2:8). The combined organic phases were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a brown viscous substance (gum).
- the obtained compound was purified by flash column chromatography and eluted with 1-15% methanol in DCM.
- the target compartment was concentrated under reduced pressure, purified by prep-HPLC, and lyophilized for 30 hours to obtain the title compound (40 mg, 0.039 mmol, 5.37 % yield) as a yellow solid.
- Step 4 Methyl 2-(4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetate (8 ) synthesis of
- Step 5 2-(4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)acetic acid (9 ) synthesis of
- Step 6 N-(2-chlorophenyl)-4-((2-((4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3- Synthesis of dioxoisoindolin-5-yl)piperazin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide (Compound 12)
- Step 1 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((3-hydroxypropyl)amino)isoindoline-1,3-dione (2)
- Step 2 3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl 4-methylbenzenesulfonate (3) synthesis
- Step 3 tert-Butyl 4-(2-(4-((4-((4-((2-chlorophenyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino Synthesis of )phenyl)acetyl)piperazine-1-carboxylate (6)
- Step 4 N-(2-chlorophenyl)-4-((5-fluoro-2-((4-(2-oxo-2-(piperazin-1-yl)ethyl)phenyl)amino)pyrimidine Synthesis of -4-yl)amino)benzamide (7)
- Step 5 N-(2-chlorophenyl)-4-((2-((4-(2-(4-(3-((2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)amino)propyl)piperazin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benz Synthesis of Amide (Compound 13)
- Step 1 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((6-hydroxyhexyl)amino)isoindoline-1,3-dione (2)
- Step 2 6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl 4-methylbenzenesulfonate (3) synthesis
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-(4-(6-((2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)amino)hexyl)piperazin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benz Synthesis of Amide (Compound 14)
- Step 1 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((8-hydroxyoctyl)amino)isoindoline-1,3-dione (2)
- Step 2 8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl 4-methylbenzenesulfonate (3) synthesis
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-(4-(8-((2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)amino)octyl)piperazin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benz Synthesis of Amide (Compound 15)
- Step 1 2-(2,6-dioxopiperidin-3-yl)-5-((3-(piperazin-1-yl)propyl)amino)isoindoline-1,3-dione (2) synthesis of
- Step 2 N-(2-chlorophenyl)-4-((2-((4-(2-(4-(3-((2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-5-yl)amino)propyl)piperazin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benz Synthesis of Amide (Compound 16)
- Step 3 Benzyl 4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl ) synthesis of piperazine-1-carboxylate (4)
- Step 5 N-(2-chlorophenyl)-4-((2-((4-(2-(4-((1-(2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazin-1-yl)-2-oxoethyl) phenyl) amino)-5-fluoropyrimidine-4 Synthesis of -yl)amino)benzamide (Compound 17)
- Step 1 Benzyl 4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl ) synthesis of piperazine-1-carboxylate (3)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-(4-((1-(2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-5-yl) piperidin-4-yl) methyl) piperazin-1-yl)-2-oxoethyl) phenyl) amino)-5-fluoropyrimidine-4 Synthesis of -yl)amino)benzamide (Compound 18)
- Step 1 Synthesis of benzyl 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)piperazine-1-carboxylate (2)
- Step 3 Benzyl 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)piperazine Synthesis of -1-carboxylate (5)
- Step 5 N-(2-Chlorophenyl)-4-((2-((4-(2-(4-(1-(2-(2,6-dioxopiperidin-3-yl))- 1,3-dioxoisoindolin-4-yl) piperidin-4-yl) piperazin-1-yl)-2-oxoethyl) phenyl) amino)-5-fluoropyrimidin-4-yl) Synthesis of amino)benzamide (compound 19)
- Step 1 Benzyl 4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)piperazine Synthesis of -1-carboxylate (3)
- Step 3 N-(2-Chlorophenyl)-4-((2-((4-(2-(4-(1-(2-(2,6-dioxopiperidin-3-yl))- 1,3-dioxoisoindolin-5-yl) piperidin-4-yl) piperazin-1-yl)-2-oxoethyl) phenyl) amino)-5-fluoropyrimidin-4-yl) Synthesis of amino)benzamide (compound 20)
- Step 1 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((5-hydroxypentyl)amino)isoindoline-1,3-dione (2)
- Step 2 5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl 4-methylbenzenesulfonate (3) synthesis
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-(4-(5-((2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)amino)pentyl)piperazin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benz Synthesis of Amide (Compound 21)
- Step 1 2-(2,6-dioxopiperidin-3-yl)-4-((4-(piperazin-1-yl)butyl)amino)isoindoline-1,3-dione (2) synthesis of
- Step 2 N-(2-chlorophenyl)-4-((2-((4-(2-(4-(4-(4-((2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)amino)butyl)piperazin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benz Synthesis of Amide (Compound 22)
- Step 1 2-(2,6-dioxopiperidin-3-yl)-4-(3-(hydroxymethyl)azetidin-1-yl)isoindoline-1,3-dione (2) synthesis
- Step 2 Synthesis of 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)azetidine-3-carbaldehyde (3)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-(4-((1-(2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl) azetidin-3-yl) methyl) piperazin-1-yl)-2-oxoethyl) phenyl) amino) -5-fluoropyrimidine-4- Synthesis of yl)amino)benzamide (Compound 23)
- Step 1 2-(2,6-dioxopiperidin-3-yl)-4-(3-(hydroxymethyl)pyrrolidin-1-yl)isoindoline-1,3-dione (3) synthesis of
- Step 2 Synthesis of 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pyrrolidine-3-carbaldehyde (4)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-(4-((1-(2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)pyrrolidin-3-yl)methyl)piperazin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidine-4 Synthesis of -yl)amino)benzamide (Compound 24)
- Step 1 tert-Butyl 4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) methyl)piperidin-1 -Synthesis of carboxylate (2)
- Step 2 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((piperidin-4-ylmethyl)amino)isoindoline-1,3-dione (3)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-(4-(((2-(2,6-dioxopiperidin-3-yl)-1, 3-dioxoisoindolin-4-yl) )amino)methyl)piperidin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide Synthesis of (Compound 25)
- Step 1 tert-Butyl 4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) propyl)piperidine Synthesis of -1-carboxylate (3)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-(4-(3-((2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)amino)propyl)piperidin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino) Synthesis of benzamide (Compound 26)
- Step 1 tert-butyl (3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) propyl)carbamate (3) synthesis of
- Step 2 Synthesis of 4-((3-aminopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (4)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-((3-((2-(2,6-dioxopiperidin-3-yl)-1, Synthesis of 3-dioxoisoindolin-4-yl))amino)propyl)amino)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide (Compound 27)
- Step 1 tert-butyl (5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)carbamate (3) synthesis of
- Step 2 Synthesis of 4-((5-aminopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (4)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-((5-((2-(2,6-dioxopiperidin-3-yl)-1, Synthesis of 3-dioxoisoindolin-4-yl))amino)pentyl)amino)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide (Compound 28)
- Step 1 Synthesis of benzyl (7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl)carbamate (3)
- Step 2 Synthesis of 4-((7-aminoheptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (4)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-((7-((2-(2,6-dioxopiperidin-3-yl))-1 Synthesis of ,3-dioxoisoindolin-4-yl)amino)heptyl)amino)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide (Compound 29)
- Step 2 Synthesis of benzyl (9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)nonyl)carbamate (4)
- Step 3 Synthesis of 4-((9-aminononyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (5)
- Step 4 N-(2-Chlorophenyl)-4-((2-((4-(2-((9-((2-(2,6-dioxopiperidin-3-yl))-1 Synthesis of ,3-dioxoisoindolin-4-yl)amino)nonyl)amino)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide (Compound 30)
- Step 2 tert-Butyl 4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl) Synthesis of methyl)piperidine-1-carboxylate (4)
- Step 4 N-(2-chlorophenyl)-4-((2-((4-(2-(4-((4-(2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)piperazin-1-yl)methyl)piperidin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidine-4 Synthesis of -yl)amino)benzamide (Compound 31)
- Step 1 2-(2,6-dioxopiperidin-3-yl)-4-(3-(hydroxymethyl)pyrrolidin-1-yl)isoindoline-1,3-dione (2) synthesis of
- Step 2 Synthesis of tert-butyl 3-(3-cyanopropylidene)azetidine-1-carboxylate (3)
- Step 3 Synthesis of tert-butyl 3-(4-aminobutyl)azetidine-1-carboxylate (4)
- Step 5 4-((4-(azetidin-3-yl)butyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (7) synthesis of
- Step 6 N-(2-chlorophenyl)-4-((2-((4-(2-(3-(4-((2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)amino)butyl)azetidin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benz Synthesis of Amide (Compound 32)
- Step 1 tert-Butyl 2-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) methyl)-7-azaspiro [3.5] Synthesis of nonane-7-carboxylate (3)
- Step 2 tert-Butyl 2-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) methyl)-7-azaspiro [3.5] Synthesis of nonane-7-carboxylate (4)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3 -dioxoisoindolin-4-yl))amino)methyl)-7-azaspiro[3.5]nonan-7-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl Synthesis of )amino)benzamide (Compound 33)
- Step 2 Synthesis of tert-butyl 3-(4-aminobutyl)pyrrolidine-1-carboxylate (3)
- Step 3 tert-Butyl 3-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)pyrrolidine Synthesis of -1-carboxylate (5)
- Step 5 N-(2-chlorophenyl)-4-((2-((4-(2-(3-(4-((2-(2,6-dioxopiperidin-3-yl))) -1,3-dioxoisoindolin-4-yl)amino)butyl)pyrrolidin-1-yl)-2-oxoethyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino) Synthesis of benzamide (compound 34)
- Step 1 tert-butyl (4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)carbamate (3) synthesis of
- Step 2 Synthesis of 4-((4-aminobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (4)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-((4-((2-(2,6-dioxopiperidin-3-yl)-1,3-di Synthesis of oxoisoindolin-4-yl)amino)butyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide (Compound 35)
- Step 1 tert-butyl (6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)carbamate (2) synthesis of
- Step 2 Synthesis of 4-((6-aminohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (3)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-di Synthesis of oxoisoindolin-4-yl)amino)hexyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide (Compound 36)
- Step 1 tert-butyl (8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)carbamate (2) synthesis of
- Step 2 4-((8-aminooctyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Synthesis of (3)
- Step 3 N-(2-Chlorophenyl)-4-((2-((4-((8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline -4-yl)amino) octyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide Synthesis of (Compound 37)
- Step 1 tert-butyl (10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)decyl)carbamate (2) synthesis of
- Step 2 Synthesis of 4-((10-aminodecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (3)
- Step 3 N-(2-chlorophenyl)-4-((2-((4-((10-((2-(2,6-dioxopiperidin-3-yl)-1,3-di Synthesis of oxoisoindolin-4-yl)amino)decyl)carbamoyl)phenyl)amino)-5-fluoropyrimidin-4-yl)amino)benzamide (Compound 38)
- the MDA-MB-231 cell line was purchased from Korea Cell Line Bank. Passage of cultured cells was maintained around P50.
- Thermo's cell counter (Catalog # AMQAX1000) and 0.4% trypan blue solution were used.
- 3 ⁇ 10 5 cells were seeded in each well of a 12-well plate (SPL), and the cells were cultured in a culture medium volume of 1 mL.
- the compound was completely dissolved in DMSO (Sigma, Cat. No. D2438; Lot. No. RNBK1809) and used in the experiment, and the concentration of DMSO treated in each well was unified at 0.1%, and treated by adding it intracellularly. .
- the concentration treated in each well is as indicated in the blot image.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (11)
- 하기 화학식 Ⅰ로 표시되는 화합물, 이의 입체 이성질체 또는 이의 약학적으로 허용가능한 염:[화학식 Ⅰ]상기 화학식 Ⅰ에서,ULM은 하기 화학식 A 또는 화학식 B로 표시되는 E3 유비퀴틴 라이게이즈 결합 모이어티이고,[화학식 A]{상기 화학식 A에서,X1은 단일결합, -CH2-, -NH-, -O-, -CH2CH2-, -CC- -CO-, -COO-, -NHCO- 또는 -CONH-이고;X2는 -CH2-, -CH(C1-4알킬)-, -NH-, -N(C1-4알킬)-, -O-, -CO-, -CH2-CH2-, -NH-CH2-, -NH-CH(C1-4알킬)-, -N=CH-, -N=C(C1-4알킬)- 또는 -N=N-이고,X3은 수소이고;X4는 수소, 할로겐, C1-6알킬, CN, NH2, NO2, OH, COH, COOH 또는 CF3임.}[화학식 B]{상기 화학식 B에서,n은 1 내지 3의 정수이고,Y1은 수소 또는 C1-3알킬임}PTM은 하기 화학식 Ⅱ로 표시되는 AURKA 결합 모이어티이며,[화학식 Ⅱ]{상기 화학식 Ⅱ에서,R1 및 R2는 각각 독립적으로 수소, -NO2, -CN, -OH, C1-6알킬, C2-6알케닐, C2-6알키닐, C1-6알콕시, C1-6티오알콕시, C3-6시클로알킬, C3-6헤테로시클로알킬, C3-6헤테로아릴, 페닐 또는 할로겐이고,R3는 C1-6알킬렌, -O-, -S-, -NH-, 또는 직접결합이며,Linker는 ULM과 PTM을 화학적으로 연결하는 기이고, 하기 화학식 L로 표시됨:[화학식 L]LULM 및 LPTM은 각각 독립적으로 단일결합, -CH2-, -NH-, -O-, -CO-, -OCO-, -CONH-, -NHCO-, -O(CH)nCONH-{여기서, n은 1 내지 5의 정수임}, 또는 직접결합이며,LINT는 C1-10알킬렌, -CH2-, -NH-, -O(CH)nCONH-{여기서, n은 1 내지 5의 정수임}, -(CH2)lO(CH2)mO(CH2)q-{여기서, l, m 및 q는 독립적으로 1 내지 5의 정수임}, -CHCH-, -CC-, -CH2CH2O-, -OCH2CH2-, -CH2CH2S-, -SCH2CH2-, -COO-, -CONH-, -NHCO-, 및 직접결합으로 구성된 군에서 선택되며{여기서, 은 아릴, 헤테로아릴, 3 내지 10원 사이클로알킬, 4원 내지 10원 헤테로사이클로알킬, 4 내지 10원 사이클로알케닐, 및 4 내지 10원 헤테로사이클로알케닐로 구성된 군에서 선택된 고리임},LULM, LPTM 및 LINT는 각각 독립적으로 1 이상의 C1-6알킬, C3-8사이클로알킬, C3-8헤테로사이클로알킬, 할로겐, 히드록시, 아민, 니트로, 시아노 또는 C1-8할로알킬로 치환될 수 있으며,p는 1 내지 20의 정수이다.
- 제1항에 있어서,상기 화학식 Ⅰ로 표시되는 화합물은 AURKA 단백질의 선택적 분해를 유도하는 것인, 화합물, 이의 입체이성질체 또는 이의 약학적으로 허용가능한 염.
- 제1항 내지 제7항 중 어느 한 항에 따른 화합물, 이의 입체이성질체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물.
- 제9항에 있어서,상기 암은 편평상피세포암, 소세포폐암, 비소세포폐암, 폐의 선암, 폐의 편평상피암, 복막암, 피부암, 피부 또는 안구내 흑색종, 직장암, 항문부근암, 식도암, 소장암, 내분비선암, 부갑상선암, 부신암, 연조직 육종, 요도암, 만성 또는 급성 백혈병, 림프구 림프종, 골수섬유증, 간세포암, 위장암, 위암, 췌장암, 교아종, 경부암, 난소암, 간암, 방광암, 간종양, 유방암, 결장암, 대장암, 자궁내막 또는 자궁암, 침샘암, 신장암, 전립선암, 음문암, 갑상선암, 두경부암, 뇌암, 골육종, 배럿 식도, 대장 선종 및 용종, 유방 섬유선종 및 낭종, 단세포 감마글로불린병증 (MGUS), 단클론 림프구증가증으로 이루어진 군으로부터 선택되는 AURKA 관련 암인, 약학적 조성물.
- 제1항 내지 제7항 중 어느 한 항에 따른 화합물, 이의 입체이성질체 또는 이의 약학적으로 허용가능한 염을 이를 필요로 하는 개체에 투여하는 단계를 포함하는, 암 예방 또는 치료 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237042847A KR20240008889A (ko) | 2021-06-24 | 2022-06-24 | Aurka 선택적 분해 유도 화합물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163214600P | 2021-06-24 | 2021-06-24 | |
US63/214,600 | 2021-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022270987A1 true WO2022270987A1 (ko) | 2022-12-29 |
Family
ID=84544674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/009074 WO2022270987A1 (ko) | 2021-06-24 | 2022-06-24 | Aurka 선택적 분해 유도 화합물 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20240008889A (ko) |
WO (1) | WO2022270987A1 (ko) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106674197A (zh) * | 2015-11-09 | 2017-05-17 | 兰州大学 | 一种极光激酶a抑制剂及其制备与应用 |
KR20180097530A (ko) * | 2015-11-02 | 2018-08-31 | 예일 유니버시티 | 단백질분해 표적화 키메라 화합물(Proteolysis Targeting Chimera compound) 및 그의 제조 및 사용 방법 |
-
2022
- 2022-06-24 WO PCT/KR2022/009074 patent/WO2022270987A1/ko active Application Filing
- 2022-06-24 KR KR1020237042847A patent/KR20240008889A/ko unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180097530A (ko) * | 2015-11-02 | 2018-08-31 | 예일 유니버시티 | 단백질분해 표적화 키메라 화합물(Proteolysis Targeting Chimera compound) 및 그의 제조 및 사용 방법 |
CN106674197A (zh) * | 2015-11-09 | 2017-05-17 | 兰州大学 | 一种极光激酶a抑制剂及其制备与应用 |
Non-Patent Citations (3)
Title |
---|
ADHIKARI BIKASH; BOZILOVIC JELENA; DIEBOLD MATHIAS; SCHWARZ JESSICA DENISE; HOFSTETTER JULIA; SCHRöDER MARTIN; WANIOR MAREK; : "PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase", NATURE CHEMICAL BIOLOGY, vol. 16, no. 11, 28 September 2020 (2020-09-28), New York, pages 1179 - 1188, XP037272574, ISSN: 1552-4450, DOI: 10.1038/s41589-020-00652-y * |
HE MING, LV WENXING, RAO YU: "Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation", FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. 9, no. 685106, pages 1 - 25, XP093017040, DOI: 10.3389/fcell.2021.685106 * |
IGNACIO ALIAGAS-MARTIN, DAN BURDICK, LAURA CORSON, JENNAFER DOTSON, JASON DRUMMOND, CARTER FIELDS, OSCAR W. HUANG, THOMAS HUNSAKER: "A Class of 2,4-Bisanilinopyrimidine Aurora A Inhibitors with Unusually High Selectivity against Aurora B †", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 10, 28 May 2009 (2009-05-28), US , pages 3300 - 3307, XP055230790, ISSN: 0022-2623, DOI: 10.1021/jm9000314 * |
Also Published As
Publication number | Publication date |
---|---|
KR20240008889A (ko) | 2024-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021194320A1 (en) | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 | |
WO2019190259A1 (ko) | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 | |
EP3116859A1 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
WO2021162493A1 (ko) | 단백질 키나아제 분해 유도 화합물 및 이의 용도 | |
WO2023018155A1 (ko) | Shp2 단백질 분해활성을 갖는 화합물 및 이들의 의약 용도 | |
WO2022250350A1 (ko) | 피페리딘디온 유도체 | |
AU2021225683B2 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
WO2012134188A2 (ko) | 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 | |
WO2021125802A1 (ko) | 신규한 인다졸 유도체 및 이의 용도 | |
WO2016006974A2 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
WO2023018238A1 (en) | Novel plk1 degradation inducing compound | |
WO2018021826A1 (ko) | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2022270987A1 (ko) | Aurka 선택적 분해 유도 화합물 | |
AU2021255176B2 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
WO2018139883A1 (ko) | 다중 표적 키나아제 저해제로서 융합피리미딘 유도체 | |
WO2022019597A1 (ko) | 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도 | |
EP3166945A2 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
WO2022098108A1 (ko) | Nlrp3 단백질 분해 유도 화합물 | |
WO2024112120A1 (ko) | 신규한 c-MET 단백질 리간드를 포함하는 디그레이더 및 이를 포함하는 약학 조성물 | |
WO2021080346A1 (ko) | 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 | |
WO2024106979A1 (ko) | 피페리딘 유도체, 이의 염 및 이를 유효성분으로 포함하는 약학적 조성물 | |
WO2024019562A1 (ko) | 헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물 | |
WO2023132606A1 (ko) | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 | |
WO2024054071A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and uses thereof | |
WO2022145989A1 (ko) | 선택적 plk1 억제제로서의 피리미도디아제핀 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22828834 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20237042847 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237042847 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18569677 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22828834 Country of ref document: EP Kind code of ref document: A1 |